SCYNEXIS wins BARDA contract worth up to $214 million for SCY-247 development

• SCYNEXIS won a BARDA contract worth up to USD 214 million to fund development of its SCY-247 antifungal through potential NDA submissions.
• Base period provides USD 18.5 million to move oral and IV SCY-247 into a Phase 2 trial for invasive candidiasis.
• Contract includes an option to support a second indication focused on prevention in high-risk patients; term can extend up to 10 years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280730PRIMZONEFULLFEED9834679) on September 28, 2026, and is solely responsible for the information contained therein.